AARDEX Group

NIH Adherence Network Distinguished Speaker Webinar Series, February 17, 2016

adherence_Research
FEB-2016 : High-fidelity measurement of patients’ medication adherence

FEB-2016 : High-fidelity measurement of patients’ medication adherence: A missing link in precision medicine

Abstract

Patient nonadherence to prescribed medicines is endemic and thus a central issue in the quality and economics of ambulatory medical care and drug trials. To be efficacious, a course of drug treatment must have a timely initiation, and treatment persistence is required for an evidence-based period of time. Precision medicine is currently facing additional requirements where, for most therapeutic areas under investigation, the drugs’ therapeutic windows are narrow. These are pre-conditions for identifying optimal dosage regimens that best balance safety and efficacy, and require precise implementation of the dosing regimen for optimal outcomes of treatment. Yet adherence research shows wide variability in ambulatory patients’ timing and taking of doses, relative to protocol-specified, or label-specified, dosing regimens, thereby creating a major source of variance in drug exposure.

This situation points to the need for adherence-informed research in which exposure to the test drugs is measured with high fidelity to assess dose-dependent effectiveness. Non-intrusive, reliable, and continuous assessment of patient adherence can be achieved by automatic compilation of drug dosing history data using electronic detection methods with conventionally designed drug packages (“smart packages”). The resulting data provide dosing histories, which allow one to identify crucial errors in dosing that can jeopardize treatment outcomes, and can, in turn, be used to focus intervention to achieve precise implementation of, and long-term persistence with, the dosing regimen that is optimal for each drug being prescribed or studied. 

Register here …

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,